Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14246980 | 1.00 | NOS3 (0.36) | NOS3NOS1NOS2THRBMAPT | |
| SCHEMBL19576613 | 1.00 | NOS3 (0.36) | NOS3NOS1NOS2THRBMAPT | |
| SCHEMBL9833852 | 0.88 | NOS3 (0.34) | NOS3NOS1NOS2 | |
| SCHEMBL9452653 | 0.74 | — | — | |
| SCHEMBL28982087 | 0.74 | — | — | |
| SCHEMBL497088 | 0.72 | TSHR (0.36) | NOS3NOS1NOS2 | |
| SCHEMBL18924168 | 0.72 | TSHR (0.36) | NOS3NOS1NOS2 | |
| SCHEMBL18202924 | 0.72 | TSHR (0.36) | NOS3NOS1NOS2 | |
| SCHEMBL9207187 | 0.71 | — | — | |
| SCHEMBL51641 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0430771-B1 | Isoindolone derivatives, their preparation and their use as intermediates for the preparation of substance P antagonists | RHONE POULENC SANTE (FR) | 1994-07-20 | — | — | EP | claimed |
| EP-0430771-A1 | Isoindolone derivatives, their preparation and their use as intermediates for the preparation of substance P antagonists | RHONE-POULENC SANTE (FR) | 1991-06-05 | — | — | EP | claimed |
| WO-2024011214-A1 | THERAPEUTIC COMPOUNDS AND METHODS | ACTIO BIOSCIENCES, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| EP-3452485-B1 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | ONCOARENDI THERAPEUTICS SA (PL) | 2020-09-09 | — | — | EP | disclosed |
| EP-2720697-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-07-20 | — | — | EP | disclosed |
| US-8927585-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-01-06 | — | — | US | disclosed |
| US-8790548-B2 | Carbonaceous materials | UNIVERSITY OF YORK (GB) | 2014-07-29 | — | — | US | disclosed |
| US-8790548-B2 | Carbonaceous materials | UNIVERSITY OF YORK (GB) | 2014-07-29 | — | — | US | disclosed |
| US-20140135369-A1 | TRPV4 ANTAGONISTS | GlaxoSmith Kline,LLC (US) | 2014-05-15 | — | — | US | disclosed |
| EP-2720697-A1 | TRPV4 ANTAGONISTS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2014-04-23 | — | — | EP | disclosed |
| CN-101597286-B | Organic catalyst containing primary amine, tertiary amine and urea or thiourea and preparation method thereof | DALIAN CHEMICAL PHYSICS INST | 2013-04-03 | — | — | CN | disclosed |
| WO-2006080043-A2 | ORGANIC COMPOUNDS USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE, THEIR USE AND METHOD OF PREPARATION | ALMA MATER STUDIORUM- UNIVERSITA' DI BOLOGNA (IT) | 2006-08-03 | — | — | WO | disclosed |
| EP-0430771-B1 | Isoindolone derivatives, their preparation and their use as intermediates for the preparation of substance P antagonists | RHONE POULENC SANTE (FR) | 1994-07-20 | — | — | EP | disclosed |
| EP-0430771-A1 | Isoindolone derivatives, their preparation and their use as intermediates for the preparation of substance P antagonists | RHONE-POULENC SANTE (FR) | 1991-06-05 | — | — | EP | disclosed |
| EP-0242518-B1 | Cycloalkano[1,2-b]indole-sulfonamides | BAYER AG (DE) | 1991-04-10 | — | — | EP | disclosed |
| US-4988820-A | Inhibiting platelet aggregation, anticoagulants, thromboxane a2 antagonist | BAYER AKTIENGESELLSCHAFT (DE) | 1991-01-29 | — | — | US | disclosed |
| US-4965258-A | Anticoagulant; thromboxane a2 antagonist | BAYER AKTIENGESELLSCHAFT (DE) | 1990-10-23 | — | — | US | disclosed |
| US-4904797-A | REACTING A (BENZENESULFONAMIDOALKYL)CYCLOALKANO(1,2-B)INDOLE WITH ACRYLONITRILE; HYDROLYSIS, HYDROGENATION, REDUCTION | BAYER AKTIENGESELLSCHAFT (DE) | 1990-02-27 | — | — | US | disclosed |
| US-4827032-A | INTERMEDIATES FOR ANTICOAGULANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-05-02 | — | — | US | disclosed |
| EP-0242518-A1 | Cycloalkano[1,2-b]indole-sulfonamides | BAYER AG (DE) | 1987-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135369-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV3, TRPV5 | NOS3 3378/4885NOS1 4256/4885NOS2 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.